UroGen Pharma's three largest insider shareholders as of August 29, 2026 are Ran Nussbaum (Director, 1.48Mn shares), Arie Belldegrun (Director, 408.69K shares), Elizabeth A. Barrett (Chief Executive Officer, 326.69K shares).
| # | Insider | Position | Direct | Indirect | Total | Share of Insiders | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Ran Nussbaum | Director | 0 | 1,481,927 | 1,481,927 | 57.4% | 25 Oct, 2022 |
| 2 | Arie Belldegrun | Director | 408,693 | 0 | 408,693 | 15.8% | 16 Sep, 2022 |
| 3 | Elizabeth A. Barrett | Chief Executive Officer | 326,691 | 0 | 326,691 | 12.7% | 02 Feb, 2023 |
| 4 | Mark Schoenberg | Chief Medical Officer | 178,849 | 0 | 178,849 | 6.9% | 24 Aug, 2026 |
| 5 | Fred E Cohen | Director | 0 | 69,339 | 69,339 | 2.7% | 28 Jul, 2023 |
| 6 | Jason Drew Smith | General Counsel | 55,588 | 0 | 55,588 | 2.2% | 11 Feb, 2026 |
| 7 | Dong Kim | Chief Financial Officer | 37,753 | 0 | 37,753 | 1.5% | 12 Sep, 2024 |
| 8 | James A. Jr. Robinson | Director | 8,000 | 0 | 8,000 | 0.3% | 28 Aug, 2026 |
| 9 | Molly Henderson | Chief Financial Officer | 5,248 | 0 | 5,248 | 0.2% | 01 Feb, 2022 |
| 10 | Chris Degnan | Chief Financial Officer | 2,280 | 0 | 2,280 | 0.1% | 09 Oct, 2025 |
| 11 | Daniel George Wildman | Director | 2,000 | 0 | 2,000 | 0.1% | 01 Dec, 2025 |
| 12 | Stuart Holden | Director | 2,000 | 0 | 2,000 | 0.1% | 01 Dec, 2025 |
| 13 | Cynthia M Butitta | Director | 2,000 | 0 | 2,000 | 0.1% | 01 Dec, 2025 |
Each row is that insider’s most recently reported position, from Form 4 filings over the last 60 months — which is why this total does not tie to the quarterly series above, where a quarter counts only the insiders who filed in it. Shares held through a fund or institutional portfolio are counted on the institutional ownership page instead.
| Date | Insider | Position | Transaction | Shares | Price | Value | Shares Held After | Ownership |
|---|---|---|---|---|---|---|---|---|
| 26 Aug, 2026 | James A. Jr. Robinson | Director | Acquired M | 2,000 | — | — | 8,000 | Direct |
| 26 Aug, 2026 | James A. Jr. Robinson | Director | Disposed M | 2,000 | $0.00 | $0 | 0 | Direct |
| 20 Aug, 2026 | Mark Schoenberg | Chief Medical Officer | Disposed S | 60,677 | $47.05 | $2.85Mn | 59,086 | Direct |
| 09 Jul, 2026 | Mark Schoenberg | Chief Medical Officer | Disposed S | 10,000 | $40.00 | $400.00K | 119,763 | Direct |
| 22 Jun, 2026 | Arie Belldegrun | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 22 Jun, 2026 | Mark Schoenberg | Chief Medical Officer | Disposed S | 10,000 | $35.01 | $350.10K | 129,763 | Direct |
| 22 Jun, 2026 | Daniel George Wildman | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |
| 22 Jun, 2026 | Leana Wen | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |
| 22 Jun, 2026 | James A. Jr. Robinson | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |
| 22 Jun, 2026 | Stuart Holden | Director | Acquired A | 20,000 | $0.00 | $0 | 20,000 | Direct |
| 22 Jun, 2026 | Daniel George Wildman | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |
| 22 Jun, 2026 | Cynthia M Butitta | Director | Acquired A | 10,000 | $0.00 | $0 | 10,000 | Direct |
| 22 Jun, 2026 | Daniel George Wildman | Director | Acquired A | 8,000 | $0.00 | $0 | 8,000 | Direct |
| 22 Jun, 2026 | Cynthia M Butitta | Director | Acquired A | 8,000 | $0.00 | $0 | 8,000 | Direct |
| 22 Jun, 2026 | James A. Jr. Robinson | Director | Acquired A | 8,000 | $0.00 | $0 | 8,000 | Direct |
| 22 Jun, 2026 | Leana Wen | Director | Acquired A | 8,000 | $0.00 | $0 | 8,000 | Direct |
| 22 Jun, 2026 | Daniel George Wildman | Director | Acquired A | 8,000 | $0.00 | $0 | 8,000 | Direct |
| 08 Jun, 2026 | Mark Schoenberg | Chief Medical Officer | Acquired M | 10,000 | — | — | 144,985 | Direct |
| 08 Jun, 2026 | Mark Schoenberg | Chief Medical Officer | Disposed S | 5,222 | $27.30 | $142.56K | 139,763 | Direct |
| 08 Jun, 2026 | Mark Schoenberg | Chief Medical Officer | Disposed M | 10,000 | $0.00 | $0 | 0 | Direct |